| ID Source | ID |
|---|---|
| PubMed CID | 44142065 |
| CHEMBL ID | 566501 |
| CHEBI ID | 93643 |
| Synonym |
|---|
| NCGC00183244-01 |
| smr001318044 |
| MLS002276506 |
| CHEMBL566501 , |
| bdbm50302979 |
| 6-(3-methoxyphenyl)-n-((4-methylthiophen-2-yl)methyl)quinazolin-4-amine |
| HMS2204C23 |
| HMS3329F21 |
| CHEBI:93643 |
| 6-(3-methoxyphenyl)-n-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine |
| Q27165335 |
| Class | Description |
|---|---|
| quinazolines | Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 14.5750 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
| dual specificity tyrosine-phosphorylation-regulated kinase 1A isoform 1 | Homo sapiens (human) | Potency | 5.8246 | 0.0130 | 7.4878 | 29.1922 | AID493206 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 79.4328 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
| dual specificity protein kinase CLK4 | Homo sapiens (human) | Potency | 0.9815 | 0.0116 | 3.7867 | 31.6228 | AID1969; AID1970; AID1983 |
| Adenosine receptor A1 | Rattus norvegicus (Norway rat) | Potency | 0.8913 | 0.0631 | 4.1371 | 15.8489 | AID1969 |
| Adenosine receptor A3 | Rattus norvegicus (Norway rat) | Potency | 0.8913 | 0.0631 | 3.8038 | 14.1254 | AID1969 |
| Adenosine receptor A2b | Rattus norvegicus (Norway rat) | Potency | 0.8913 | 0.0631 | 3.8038 | 14.1254 | AID1969 |
| Adenosine receptor A2a | Rattus norvegicus (Norway rat) | Potency | 0.8913 | 0.0631 | 3.8038 | 14.1254 | AID1969 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| interleukin-8 isoform 1 precursor | Homo sapiens (human) | IC50 (µMol) | 8.8850 | 0.5507 | 4.3977 | 18.7700 | AID624343; AID624347 |
| Dual specificity protein kinase CLK4 | Homo sapiens (human) | IC50 (µMol) | 1.0000 | 0.0110 | 1.0694 | 7.9430 | AID445566 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| regulation of RNA splicing | Dual specificity protein kinase CLK4 | Homo sapiens (human) |
| peptidyl-tyrosine phosphorylation | Dual specificity protein kinase CLK4 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| G protein-coupled adenosine receptor activity | Adenosine receptor A2a | Rattus norvegicus (Norway rat) |
| protein serine/threonine kinase activity | Dual specificity protein kinase CLK4 | Homo sapiens (human) |
| protein serine/threonine/tyrosine kinase activity | Dual specificity protein kinase CLK4 | Homo sapiens (human) |
| protein binding | Dual specificity protein kinase CLK4 | Homo sapiens (human) |
| ATP binding | Dual specificity protein kinase CLK4 | Homo sapiens (human) |
| protein serine kinase activity | Dual specificity protein kinase CLK4 | Homo sapiens (human) |
| protein tyrosine kinase activity | Dual specificity protein kinase CLK4 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| Golgi membrane | Adenosine receptor A2a | Rattus norvegicus (Norway rat) |
| nucleus | Dual specificity protein kinase CLK4 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID445566 | Inhibition of Clk4 | 2009 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23 | Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk). |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.41) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||